Action de l’ochracine, phytotoxine de Septoria nodorum Berk., sur le cycle mitotique de Triticum aestivum L.

National audienceOchracine changes the mitotic cycle parameters by reducing the cell flow at the transition point G1/S and lengthening G2 (X 1,4) and mitosis (x 1,8). It does not modify the relative proportions of mitosis phases. With an ochracine concentration of 65 μg. m-1, the labeling index (IL) of the S phase and the mitotic index (IM) are reduced to about 0,65 x their normal value and they seem to be practically constant during 96 h of observation. The observed latency period (very short for IL, 4 h for IM) is followed by a transition period comprised between 2 and 8 h for IL, 4 and 12 h for IM. It is only during the action period that appears the important inhibition synergy of ochracine with colchicine that inhibits’quickly the whole cell flow.L’ochracine intervient sur le cycle mitotique par un blocage partiel en G1/S et un allongement des durées de G2 (x 1,4) et de la mitose (x 1,8) sans modification apparente des proportions relatives des phases mitotiques s.s. pour une concentration en ochracine de 65 μg. m1-1. Les valeurs d’index de marquage (IL) pour la phase S et d’index mitotique (IM) sont réduites à 0,65 environ de leur valeur normale et paraissent sensiblement constantes pendant la durée des observations (96 h). La période de latence observée (peu nette pour IL et de 4 h pour IM) est suivie d’une période de transition comprise entre 2 et 8 h pour IL, 4 et 12 h pour IM. C’est seulement pendant la période d’action que se manifeste la synergie d’inhibition remarquable de l’ochracine avec la colchicine qui tend à bloquer rapidement et totalement l’ensemble du flux cellulaire. Cet effet inhibiteur paraît d’autant plus marqué que la durée d’action préalable de l’ochracine seule a été plus longue (entre 16 et 72 h)

Action de l’ochracine, phytotoxine de Septoria nodorum Berk., sur le cycle mitotique de Triticum aestivum L.

National audienceOchracine changes the mitotic cycle parameters by reducing the cell flow at the transition point G1/S and lengthening G2 (X 1,4) and mitosis (x 1,8). It does not modify the relative proportions of mitosis phases. With an ochracine concentration of 65 μg. m-1, the labeling index (IL) of the S phase and the mitotic index (IM) are reduced to about 0,65 x their normal value and they seem to be practically constant during 96 h of observation. The observed latency period (very short for IL, 4 h for IM) is followed by a transition period comprised between 2 and 8 h for IL, 4 and 12 h for IM. It is only during the action period that appears the important inhibition synergy of ochracine with colchicine that inhibits’quickly the whole cell flow.L’ochracine intervient sur le cycle mitotique par un blocage partiel en G1/S et un allongement des durées de G2 (x 1,4) et de la mitose (x 1,8) sans modification apparente des proportions relatives des phases mitotiques s.s. pour une concentration en ochracine de 65 μg. m1-1. Les valeurs d’index de marquage (IL) pour la phase S et d’index mitotique (IM) sont réduites à 0,65 environ de leur valeur normale et paraissent sensiblement constantes pendant la durée des observations (96 h). La période de latence observée (peu nette pour IL et de 4 h pour IM) est suivie d’une période de transition comprise entre 2 et 8 h pour IL, 4 et 12 h pour IM. C’est seulement pendant la période d’action que se manifeste la synergie d’inhibition remarquable de l’ochracine avec la colchicine qui tend à bloquer rapidement et totalement l’ensemble du flux cellulaire. Cet effet inhibiteur paraît d’autant plus marqué que la durée d’action préalable de l’ochracine seule a été plus longue (entre 16 et 72 h)

Action de l’ochracine, phytotoxine de Septoria nodorum Berk., sur le cycle mitotique de Triticum aestivum L.

National audienceOchracine changes the mitotic cycle parameters by reducing the cell flow at the transition point G1/S and lengthening G2 (X 1,4) and mitosis (x 1,8). It does not modify the relative proportions of mitosis phases. With an ochracine concentration of 65 μg. m-1, the labeling index (IL) of the S phase and the mitotic index (IM) are reduced to about 0,65 x their normal value and they seem to be practically constant during 96 h of observation. The observed latency period (very short for IL, 4 h for IM) is followed by a transition period comprised between 2 and 8 h for IL, 4 and 12 h for IM. It is only during the action period that appears the important inhibition synergy of ochracine with colchicine that inhibits’quickly the whole cell flow.L’ochracine intervient sur le cycle mitotique par un blocage partiel en G1/S et un allongement des durées de G2 (x 1,4) et de la mitose (x 1,8) sans modification apparente des proportions relatives des phases mitotiques s.s. pour une concentration en ochracine de 65 μg. m1-1. Les valeurs d’index de marquage (IL) pour la phase S et d’index mitotique (IM) sont réduites à 0,65 environ de leur valeur normale et paraissent sensiblement constantes pendant la durée des observations (96 h). La période de latence observée (peu nette pour IL et de 4 h pour IM) est suivie d’une période de transition comprise entre 2 et 8 h pour IL, 4 et 12 h pour IM. C’est seulement pendant la période d’action que se manifeste la synergie d’inhibition remarquable de l’ochracine avec la colchicine qui tend à bloquer rapidement et totalement l’ensemble du flux cellulaire. Cet effet inhibiteur paraît d’autant plus marqué que la durée d’action préalable de l’ochracine seule a été plus longue (entre 16 et 72 h)

The first case of intracranial rosai dorfman disease.

Objective: to report an interesting and informative case of an atypical presentation of a rare condition, Rosai Dorfman Disease (RDD) Background: RDD previously known as Sinus Histiocytosis with massive lymphadenopathy (SHML), is a rare, idiopathic disease seen mainly in children and young adults. It typically presents with painless lymphadenopathy, fever, leukocytosis, elevated erythrocyte sedimentation rate, and polyclonal hypergammaglobulinemia. To date only 5 cases of isolated epibulbar disease have been described in the literature. Case, Methods: An 80 year-old African-American woman presented with a history of a right orbital mass and complaints of worsening blurred vision and photophobia in the left eye. Her vision was NLP in the right and 20/60 in the left eye. She had a large, pink lesions under the superior bulbar conjunctiva of both eyes with concomitant cell and flare. MRI orbits, biopsies of right subconjunctival lesion and both retrobulbar lesions. Pathology showed histiocytes with abundant atypical reticular cytoplasm with phagocytosed lymphocytes. Immunohistochemical staining was S-100 positive, CD1a negative, and CD68 positive for histiocytes. Results: Enhancing soft tissue masses posterior to both globes, and masses in the cavernous sinus, cribriform plate, crista Galli, and interhemispheric fissure on either side of the falx, the left optic nerve sheath Conclusions: RDD is associated with massive cervical lymphadenopathy in 90[percnt] of patients, lymphadenopathy is also present inguinal (26[percnt]), axillary (24[percnt]), and mediastinal (15[percnt]). Up to 43[percnt] of patients presented with extranodal pathology, most frequently involving the skin, upper respiratory system, eyelid, orbit, bone, salivary glands, and the central nervous system. Our case is classified as RDD with orbital, uveal, epibulbar and intracranial involvement. The age of presentation is atypical, suggesting that RDD may masquerade as several entities and should be kept in the differential for patients with any combination of orbital masses, idiopathic uveitis, and subconjunctival lesions

Comparing the Acute Presentation of Sport-Related Concussion in the Pediatric and Adult Populations.

Despite growing research on concussion, there is minimal evidence comparing the acute presentation of concussion between pediatric and adult patients. This cross-sectional study compares injury characteristics, symptoms, and neurologic examination in sport-related concussion based on age. Patients presenting to an outpatient sports neurology clinic for initial assessment of concussion within 7 days of injury were divided into 2 groups, 18 and older (n = 28) and 17 and younger (n = 107). There were no significant differences between pediatric and adult patients in any score of the Sport Concussion Assessment Tool-3rd Edition symptom scale, neurologic examination category, pertinent elements of past medical history, or characteristics of the concussion. The pediatric group had higher average hours of sleep (8.1 ± 0.3 vs 7.1 ± 0.58; P = .03) and were less likely to wake refreshed (36.3% vs 65%; P = .02). The initial presentation of concussion within 7 days of injury will likely not differ by age, specifically 18 and older versus 17 and younger